Skip to main content

Breaking down the facts of Ozempic (semaglutide), a type 2 diabetes treatment

(BPT) - Novo Nordisk is a healthcare company with a 100­-year history of driving change to improve the lives of people living with serious, chronic diseases. As broader conversations about diabetes medicines are ongoing in both mainstream and social media, we believe it is important to continue to raise awareness and to reinforce our commitment to responsible use of Novo Nordisk medicines. These efforts are intended to support the safety of all people for one of our medicines that is well known in the diabetes community, Ozempic®.

See Medication Guide: bit.ly/OzempicPI & Safety Info: bit.ly/OzempicISI for Ozempic (semaglutide) injection 0.5 mg, 1 mg, or 2 mg.

Infographic addressing misinformation regarding Ozempic


Recent Quotes

View More
Symbol Price Change (%)
AMZN  226.97
-3.34 (-1.45%)
AAPL  269.66
-0.04 (-0.01%)
AMD  257.96
-6.37 (-2.41%)
BAC  53.05
+0.47 (0.89%)
GOOG  290.56
+15.39 (5.59%)
META  660.00
-91.67 (-12.20%)
MSFT  529.02
-12.53 (-2.31%)
NVDA  202.44
-4.60 (-2.22%)
ORCL  263.08
-12.22 (-4.44%)
TSLA  445.28
-16.23 (-3.52%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.